These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 3292151

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Clinical administration of epoetin alfa recombinant.
    Taylor BA, Weinstein SM.
    J Intraven Nurs; 1992; 15(2):78-82. PubMed ID: 1564606
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Recombinant human erythropoietin for anaemia associated with chronic renal failure in predialysis patients.
    Schaefer RM, Schaefer L, Heidland A.
    Przegl Lek; 1992; 49(1-2):41-2. PubMed ID: 1455005
    [No Abstract] [Full Text] [Related]

  • 48. In vitro and in vivo effects of recombinant human erythropoietin on human hemopoietic progenitor cells.
    Ganser A, Bergmann M, Völkers B, Grützmacher P, Hoelzer D.
    Contrib Nephrol; 1988; 66():123-30. PubMed ID: 3292145
    [No Abstract] [Full Text] [Related]

  • 49. Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation.
    Am J Kidney Dis; 1989 Sep; 14(3):163-9. PubMed ID: 2672796
    [No Abstract] [Full Text] [Related]

  • 50. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study.
    Faller B, Slingeneyer A, Waller M, Michel C, Grützmacher P, Müller HP, Barany P, Grabensee B, Issad B, Schmitt H.
    Clin Nephrol; 1993 Sep; 40(3):168-75. PubMed ID: 8403573
    [Abstract] [Full Text] [Related]

  • 51. [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy].
    Wiecek A.
    Przegl Lek; 1995 Sep; 52(3):93-4. PubMed ID: 7644683
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis.
    Grützmacher P, Bergmann M, Weinreich T, Nattermann U, Reimers E, Pollok M.
    Contrib Nephrol; 1988 Sep; 66():104-13. PubMed ID: 3292143
    [No Abstract] [Full Text] [Related]

  • 55. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
    Radermacher J, Koch KM.
    Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
    [Abstract] [Full Text] [Related]

  • 56. Recombinant human erythropoietin treatment of anemic cancer patients.
    Henry DH.
    Cancer Pract; 1996 Nov; 4(4):180-4. PubMed ID: 8900758
    [Abstract] [Full Text] [Related]

  • 57. [Recombinant human erythropoietin].
    Frenken LA, Koene RA.
    Ned Tijdschr Geneeskd; 1988 Mar 05; 132(10):432-4. PubMed ID: 3347279
    [No Abstract] [Full Text] [Related]

  • 58. Management of renal anemia.
    Peco-Antic A.
    Turk J Pediatr; 2005 Mar 05; 47 Suppl():19-27. PubMed ID: 15884663
    [Abstract] [Full Text] [Related]

  • 59. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A, McCrea JB.
    ASAIO J; 1993 Mar 05; 39(1):11-8. PubMed ID: 8439674
    [No Abstract] [Full Text] [Related]

  • 60. [Erythropoietin].
    Pavlović-Kentera V.
    Srp Arh Celok Lek; 1989 Mar 05; 117(9-10):643-8. PubMed ID: 18709763
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.